Aztreonam lysine for inhalation as a treatment for Burkholderia cepacia complex in CF.

Julie Willekens, Elke De Wachter, Iris De Schutter, E Vanderhelst, L. De Meirleir, Anne Malfroot

Research output: Contribution to journalEditorial


Objectives: Aztreonam lysine for inhalation (AZLI) has been proven effective in
the treatment of chronic Ps. aeruginosa (PA) infection in CF. It is not clear whether
patients with other infecting organisms, such as B. cepacia complex (Bcc), could
benefit from this treatment. We aim to investigate the clinical efficacy of AZLI for
Bcc in CF.
Methods: We reviewed medical files of 4 patients infected with B. multivorans who
were treated with AZLI. Bcc prevalence in Belgium is 2%.
Results: The patients were 26 (A, male, severe liver disease and portal hypertension),
33 (B female), 14 (C, female, CFRD) and 12 (D, male) years old. A was
infected for several years, whereas B, C and D were newly acquired colonisations.
A and B had co-infection with PA. A, B and C were treated for 48 weeks with AZLI
(28 day on/off cycle) as add-on therapy to another cyclical inhaled antibiotic, D for
12 weeks continuously as mono-inhaled therapy. In addition, A received 3-monthly
courses of IV antibiotics; B, C and D had 1 IV course at time of acquisition.
Mean lung function values remained stable for 48 weeks during AZLI. D showed
a slight improvement in FEV1 of 4% after 12 weeks. A did not deteriorate further.
In B and D, Bcc was not found in the respiratory cultures during AZLI inhalation.
However in D, Bcc reappeared after AZLI was stopped. B and C had less pulmonary
exacerbations after start of AZLI. No adverse effects were seen.
Conclusion: These Bcc-infected patients seem to benefit from a treatment with
AZLI. In 2 recent acquisitions, eradication of B. multivorans was seen. AZLI was
well tolerated, also in young patients. Clinical trials studying the efficacy of AZLI
for Bcc are ongoing.
Original languageEnglish
Pages (from-to)72-72
Number of pages1
JournalJournal of Cystic Fibrosis
Issue numberjune
Publication statusPublished - 2013


  • aztreonam
  • burkholderia cepacia
  • CF


Dive into the research topics of 'Aztreonam lysine for inhalation as a treatment for Burkholderia cepacia complex in CF.'. Together they form a unique fingerprint.

Cite this